The purpose of this study is to construct a multi-drug delivery, dual anti-tumor, active targeting and drug control. The invention relates to a mesoporous silicon nano material (MSN) -nucleic acid nano drug delivery system with integrated release function, to explore its inhibitory activity and mechanism on osteosarcoma. Firstly, mesoporous silicon nanomaterials (MSN) were synthesized, and PDK inhibitors and shRNA were introduced into MSN. Then, aptamers were designed to achieve active targeting of tumor cells and controlled release of drugs. Next, through cellular uptake experiments and active targeting evaluation, the active targeting of the MSN-aptamer nanodrug system to tumor cells was determined. Through cell activity and proliferation inhibition experiments, apoptosis and cell cycle analysis, and cell migration and invasion ability analysis, the dual anti-tumor activity of drug system chemistry and gene therapy was determined. Finally, the antitumor effect and toxicity of the drug system were evaluated in animal experiments. The MSN-nucleic acid nanocarrier system was successfully constructed and characterized. Through active targeting evaluation, the active targeting of the MSN-aptamer nano-drug system to tumor cells was confirmed. The drug system shows anti-tumor activity by inhibiting cell proliferation, inducing cell apoptosis and cell cycle analysis. And the experiments of inhibiting cell migration and invasion ability prove the dual anti-tumor activity of the drug system. The results of animal experiments showed the anti-tumor effect of the drug system and evaluated its toxicity. The MSN-ribonucleic acid nano-drug delivery system has the potential to be used in anti-tumor therapy. The MSN-aptamer nano-drug system achieves the targeting effect on tumor cells through an active targeting mechanism. Multiple mechanisms may be involved in the dual antitumor activities of drug systems. The results of animal experiments show the anti-tumor effect of the drug system and its potential in clinical application.

Hui Zhang, Zhan Wang, Yang Yang, Fuqiang Zhang. Mesoporous Silica Nanomaterials Targeted Delivery of PDK Inhibitor and shRNA Dual Therapy for Osteosarcoma Inhibitory Activity and Mechanism. International Journal of World Medicine (2024), Vol. 5, Issue 1: 1-10. https://doi.org/10.38007/IJWM.2024.050101.

[1]He Y, Yu B. [Retracted] MicroRNA 93 promotes cell proliferation by directly targeting P21 in osteosarcoma cells. Experimental and therapeutic medicine, 2024, 27 (3): 101-101.

[2]Wang J, Ferrena A, Zhang R, et al. Targeted inhibition of SCF^SKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma. Oncogene, 2024,

[3]Liao Y, Chen L, Feng Y, et al. Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget, 2024, 15 104-105.

[4]Zhong S, Zhang Y, Mou H, et al. Targeting PERK-ATF4-P21 axis enhances the sensitivity of osteosarcoma HOS cells to Mppα-PDT. Aging, 2024, 16 (3):

[5]Zhang F, Chen J, Luo W, et al. Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma. International Journal of Pharmaceutics, 2024, 652 123865-.

[6]Kong Y, Li X, Zhang H, et al. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo. Cell death & disease, 2024, 15 (1): 57-57.

[7]Hu J, Lazar J A, Ingram D, et al. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disruptsextracellular matrix in heterogenous osteosarcoma xenograft models. Journal for immunotherapy of cancer, 2024, 12 (1):

[8]Albert E, Francesco T, Cristina C. Engineering alginate-based injectable hydrogels combined with bioactive polymers for targeted plasma-derived oxidative stressdelivery in osteosarcoma therapy. International Journal of Biological Macromolecules, 2024, 257 (P2): 128841-.

[9]Dawei Z, Qingzhu G, Kemin Y, et al. m⁶A-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc. Journal of orthopaedic surgery and research, 2024, 19 (1): 33-33.

[10]Sun H, Kawano M, Iwasaki T, et al.MicroRNA-329-3p inhibits the Wnt/β-catenin pathway and proliferation of osteosarcoma cells by targeting transcription factor7-like 1. Oncology research, 2024, 32 (3): 463-476.

[11]Fellenberg J, Losch S, Tripel E, et al. The Warburg Trap: A Novel Therapeutic Approach for Targeting Osteosarcoma. Cells, 2023, 13 (1):

[12] Li Yesen. Synthesis and imaging of long-circulating pet probes specifically targeting highly metastatic osteosarcoma. Fujian Medical Journal, 2023, 45 (06): 127-129.

[13]Jooyeon S, Hyeonkyeong K, Jiyun M, et al. Decoupling NAD⁺ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2α axis. Cell reports. Medicine, 2023, 5 (1): 101342-101342.

[14]Rongrong G,M. G H. Targeting transforming growth factor beta signaling in metastatic osteosarcoma. Journal of Bone Oncology, 2023, 43 100513-100513.

[15]Qian J, Rong H, Ruimin H, et al. Phytic acid-modified manganese dioxide nanoparticles oligomer for magnetic resonance imaging and targeting therapy ofosteosarcoma. Drug delivery, 2023, 30 (1): 2181743-2181743.

[16]Nakano K. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results. International Journal of Molecular Sciences, 2023, 24 (23):

[17]Longhai D, Yanlong X, Binxu H, et al. EGFR-targeting peptide conjugated polymer-lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma. Journal of cancer research and therapeutics, 2023, 19 (6): 1544-1551.

[18] Zhang Jingyong, He Ming. Effect of miR-196 on proliferation of osteosarcoma cells through targeted regulation of CDK6 expression. Chinese Journal of Laboratory Diagnostics, 2023, 27 (11): 1335-1341.

[19] Yue Wuheng, Lu Minjie, Ji Xiuhai. Preparation of iRGD-modified juglone-paclitaxel nanoparticles and their inhibitory effect on human osteosarcoma cell Saos-2.Journal of Neck and Low Back Pain, 2023, 44 (06): 904-910.

[20]Chiara C, Maria C H, Pia M P, et al. Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and-sensitive human osteosarcoma cell lines. Frontiers in Pharmacology, 2023, 14

[21]Kaichuang S, Lu Y, Shen C, et al. Alendronate Pt^iv Prodrug Amphiphile for Enhanced Chemotherapy Targeting and Bone Destruction Inhibition inOsteosarcoma. Advanced healthcare materials, 2023, e2302746-e2302746.

[22] Liu Z, He L, Xiao J, et al. MiR-375 targeting MMP13 inhibits migration and invasion of osteosarcoma cells [J/OL].Advances in Biochemistry and Biophysics, 1-12 [2024-03-02]. https://doi.org/10.16476/j.pibb.2023.0391.

[23]Sheng Z, Hongtao C, Wanshun L, et al. Corrigendum: miR-766-3p targeting BCL9L suppressed tumorigenesis, epithelial-mesenchymal transition, and metastasis through the β-catenin signaling pathway in osteosarcoma cells. Frontiers in Cell and Developmental Biology, 2023, 11 1239836-1239836.

[24]Maxim Y, Archana T, Shakeel M, et al. Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody ArmedT cells. Research square, 2023